Emerging Infections Program (EIP) Non-substantive Change Request January 2015

Amy McMillen, MPH
Centers for Disease Control and Prevention
National Center for Emerging and Zoonotic Infectious Diseases
Office of the Director
1600 Clifton Rd
Atlanta GA 30333
404-639-1045
auh1@cdc.gov

Background

The National Center for National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) of the Centers for Disease Control and Prevention (CDC) is requesting approval of a non-substantive change to the approved package under OMB no. 0920-0978; expiration date 8/31/2016.

These forms are used to conduct surveillance to determine the incidence and epidemiologic characteristics of invasive disease due to *Haemophilus influenzae*, *Neisseria meningitidis*, group A *Streptococcus*, group B *Streptococcus*, and *Streptococcus pneumoniae.*, specific foodborne diseases that is captured within FoodNet, and Influenza (specifically for the All Age Influenza Hospitalization Surveillance (Flu Hosp) project).

The forms for which approval for changes and additions are being sought include:

- 1. 2015 ABCs Case Report Form (Attachment 1)
- 2. 2015 ABCs Neonatal Infection Expanded Tracking Form (Attachment 2)
- 3. New Form: 2014 ABCs Non Bacteremic Pneumococcal Disease— (Attachment 3)
- 4. 2015 FoodNet Variable list (Attachment 4)
- 5. 2014-2015 FluSurv-NET Influenza Surveillance Project Case Report Form (Attachment 5)
- 6. 2014-2015 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey (Attachment 6)
- 7. 2014-2015 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey (Spanish) (Attachment 7)
- 8. 2014-2015 FluSurv-NET Influenza Surveillance Project Consent Form (Attachment 8)
- 9. 2014-2015 FluSurv-NET Influenza Surveillance Project Consent Form (Spanish) (Attachment 9)

The changes in this package are minor, do not change the scope of a collection, and does not greatly impact the burden. The following will detail the changes to the EIP surveillance tools including description and crosswalk of changes.

<u>Active Bacterial Core surveillance (ABCs) - Active population-based laboratory surveillance for invasive bacterial diseases</u>

Detailed Description of Changes

A. 2015 ABCs Case Report Form

There is no impact on burden due to the changes on this form. The changes include:

- 1. Question 32, Receipt of pneumococcal vaccine
 - Directions below checkboxes will be changed to 'If between ≥ 3 months and <5 years of age and an isolate is available for serotyping, please complete the Invasive Pneumococcal Disease in Children expanded form'</p>
- B. 2015 ABCs Invasive Pneumococcal Disease in Children Case Report Form Burden is decreasing as data elements have been removed from the data collection tool These changes include:
 - 1. Removed capture of manufacturer and vaccine name for Diptheria/Tetanus/Pertussis (DTP or DTaP)
 - 2. Removed capture of manufacturer and vaccine name for Haemophilis influenza type B (Hib)
 - 3. Removed rows capturing influenza immunizations
 - 4. Added section on data sources for vaccination history, including
 - What information source was used to identify the health provider
 - How many health providers were contacted
 - What information sources were used to obtain vaccination history
 - C. 2015 ABCs Non-Bacteremic Case Report Form Active Bacterial Core surveillance (ABCs), a part of the Emerging Infections Program (EIP) network, is an active, laboratory, and population-based surveillance system. It is used to determine the incidence and epidemiological characteristics of invasive disease due to group A *Streptococcus* (GAS), group B *Streptococcus* (GBS), *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis*, at 10 sites located throughout the United States. Since ABCs surveillance began in 1995, a case of invasive bacterial disease has been defined as isolation from culture of one of these pathogens from a normally sterile site in a resident of the surveillance area. Data from ABCs have been used to inform the development of vaccines, to inform the Advisory Committee on Immunization Practices (ACIP) recommendations for their use and to evaluate their effectiveness after recommendations for use are in place.

On August 13, 2014, ACIP recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged ≥65 years in series with the 23-valent pneumococcal polysaccharide vaccine (PPSV23).1 Both vaccines have demonstrated efficacy against invasive pneumococcal disease (IPD) in placebo-controlled trials. One of the determining factors for recommending PCV13 to adults aged ≥65 years was its demonstrated 45% efficacy (95% confidence interval=14-65%) against vaccine-type non-bacteremic (i.e. non-invasive) pneumococcal pneumonia (NBPP) in a placebo-controlled trial conducted in the Netherlands.2 Evidence is less clear as to whether PPSV23 is effective against NBPP. The incidence of NBPP

and the effectiveness of PCV13 vaccine against NBPP have a major influence on determining which vaccine or combination of vaccines would provide the greatest health benefits at the lowest costs. Given these and other considerations, ABCs Non-Bacteremic surveillance responds to the ACIP recommendations for the need to re-evaluate the pneumococcal vaccine policy for adults in 2018.

Cross walk of 2015 form changes

A. 2015 ABCs Case Report Form

2014 form	2015 form
32. Did the patient receive	32. Did the patient receive
pneumococcal vaccination?	pneumococcal vaccination?
1 □ Yes	1 □ Yes
2 □ No	2 □ No
9 □ Unknown	9 □ Unknown
If YES, please note which	If YES, please note which
pneumococcal vaccine was received	pneumococcal vaccine was received
(Check all that apply)	(Check all that apply)
1 □ Prevnar®, 7-valent Pneumococcal	1 □ Prevnar®, 7-valent Pneumococcal
Conjugate Vaccine (PCV7)	Conjugate Vaccine (PCV7)
1 □ Prevnar-13 [®] , 13-valent	1 □ Prevnar-13 [®] , 13-valent
Pneumococcal Conjugate Vaccine	Pneumococcal Conjugate Vaccine
(PCV13)	(PCV13)
1 □ Pneumovax [®] , 23-valent	1 □ Pneumovax [®] , 23-valent
Pneumococcal Polysaccharide Vaccine (PPV23)	Pneumococcal Polysaccharide Vaccine (PPV23)
$1 \square$ Vaccine type not specified	$1 \square$ Vaccine type not specified
If between ≥3 months and <18 years of	If between ≥ 2 months and <5 years of
age and an isolate is available for	age and an isolate is available for
serotyping, please complete the	serotyping, please complete the
Invasive Pneumococcal Disease in	Invasive Pneumococcal Disease in
Children expanded form.	Children expanded form.

B. 2015 ABCs Invasive Pneumococcal Disease Case Report Form

2014 form	2015 form
Title: Active Bacterial Core	Title: Active Bacterial Core
Surveillance (ABCs) Invasive	Surveillance (ABCs) Invasive
Pneumococcal Disease in Children	Pneumococcal Disease in Children
	(aged ≥2 months to <5 years)
Indicate manufacturer for	Removed

	T
Diptheria/Tetanus/Pertussis (DTP or	
DTap) Indicate vaccine name for	Domovod
	Removed
Diptheria/Tetanus/Pertussis (DTP or	
DTap)	D
Indicate manufacturer for Haemophilus	Removed
influenzae type B (Hib)	D
Indicate vaccine name for Haemophilus	Removed
influenzae type B (Hib)	D I
Indicate dates of immunization for	Removed
influenza vaccine	D 1
Indicate manufacturer for influenza	Removed
vaccine	
Indicate vaccine name for influenza	Removed
vaccine	T.7 1 1.1
	Was health care provider information
	available from the following sources?
	Medical chart:
	□Yes
	□ Did not check
	Vaccine Degistry
	Vaccine Registry:
	□Yes
	□ No □ Did not check
	□ Did not check
	Parent/Guardian:
	Yes Yes
	☐ Did not check
	□ Refused
	If yes to any sources, how many
	providers were contacted?
	What sources were used for vaccination
	history?
	instory:
	Medical chart:
	Yes
	☐ Did not check
	L Did Hot Clieck
	Vaccine Registry:
	Yes Yes
	□ INU

□ Did not check
Primary Care Provider: □ Yes □ No
□ Did not check
Other Provider:
□Yes
□ No
□ Did not check

ABCs Change Estimates of Annualized Burden Hours from 2014 to 2015

<u>Table A.1 Estimated Annualized Burden Hours (Highlighted forms below indicate a change in burden hours in 2015)</u>

Type of Respondent	Form Name	No. of respondents	No. of responses per respondent	Avg. burden per response (in hours)	2015 Total burden (in hours)
State Health	ABCs Case Report Form	10	809	20/60	2697
Department	Invasive Methicillin-resistant Staphylococcus aureus ABCs Case Report Form	10	609	20/60	2030
	ABCs Invasive Pneumococcal Disease in Children Case Report Form	10	22	10/60	37
	New Form: ABCs Non- Bacteremic Pneumococcal Disease Case Report Form	10	100	10/60	167
	Neonatal Infection Expanded Tracking Form	10	37	20/60	123
	ABCs Legionellosis Case Report Form	10	100	20/60	333

Foodborne Diseases Active Surveillance Network (FoodNet)

Minor revisions have been made to the FoodNet surveillance tool since the last change approval in 2014; however the changes did not result in a change to estimated burden hours for those forms.

Detailed Description of Changes

- Expanded the list of responses for 'AgClinicTestType' to reflect new tests that are now being used in clinical labs.
- Added two new variables related to culture-independent testing for STEC:
 - o DXO157
 - o DXO157TestType
- Added the following new variables to capture case exposure information to be used for attribution estimates. These variables were developed by a working group consisting of CDC and state health department sites over a two-year period. Variables were pilot-tested in 4 sites for a three-month period for *Salmonella* and *Campylobacter* cases.

- o Meat and poultry
 - CEA_Beef
 - CEA_Beef_grnd
 - CEA_Beef_out
 - CEA_Beef_unckgrnd
 - CEA Chicken
 - CEA_Chx_grnd
 - CEA_Chx_out
 - CEA_Pork
 - CEA_Turkey
 - CEA_Turkey_grnd
 - CEA_Turkey_out
- o Fish and seafood
 - CEA Fish
 - CEA_Fish_unck
 - CEA Seafd
 - CEA_Seafd_unck
- Dairy
 - CEA_Dairy
 - CEA_Milk_raw
 - CEA_Odairy_raw
 - CEA Softcheese
 - CEA Softcheese raw
- o Eggs
 - CEA Eggs
 - CEA_Eggs_out
 - CEA_Eggs_unck
- O Fruits and vegetables

- CEA Berries
- CEA_Cantaloupe
- CEA_Herbs
- CEA Lettuce
- CEA_Spinach
- CEA Sprouts
- CEA_Raw_cider
- CEA_Tomatoes
- CEA Watermelon
- o Water
 - CEA_Ountreat_water
 - CEA_Sewer_water
 - CEA_Swim_treat
 - CEA_Swim_untreat
 - CEA_Well_water
- O Person-to-person
 - CEA_Sick_contact
- S Environmental
 - CEA_Bird
 - CEA_Cat
 - CEA_Dog
 - CEA_Farm_ranch
 - CEA Live poultry
 - CEA_Pig
 - CEA Pocketpet
 - CEA_Reptile_amphib
 - CEA Ruminants
 - CEA_Sick_pet

<u>Influenza - All Age Influenza Hospitalization Surveillance Project</u>

Minor revisions have been made to the FluSurv-NET Influenza Surveillance tool since the last change approval in 2014; however the changes did not result in a change to estimated burden hours for those forms.

Detailed Description of Changes

A. 2014-15 FluSurv-NET Influenza Surveillance Project_Case Report Form

- A question was added to capture the type of address provided for the patient.
- Additional questions were added to capture additional patient provider contact information.
- To better capture information on where the patient resided at the time of, additional residence type options for question C13 were added.
- Questions regarding Influenza testing results were updated to include new influenza testing types and corresponding result options.

- To better capture information regarding signs/symptoms at the time of admission, question E2 was rephrased to list signs/symptoms as they appear in medical chart but original intent of question was preserved.
- The options for specifying location of consolidation was removed from questionnaire.
- The section on vaccination status has now an option to record type of vaccination (injected or nasal spray) for children <9 years of age.

B. 2014-2015 FluSurv-NET Influenza Surveillance Project_Vaccination History Telephone Survey (Changes Account for the English and Spanish Version)

• Addition of a question to capture the type of vaccination (injected or nasal spray) received by patients <9 years of age.

C. 2014-2015 FluSurv-NET Influenza Surveillance Project_Consent Form (Changes Account for the English and Spanish Version)

• Location of reference material for continuation of interview was updated to reflect current location.

Cross walk of 2015 form changes

A. 2014-15 FluSurv-NET Influenza Surveillance Project_Case Report Form

Question on 2013-14 Form	Question on 2014-15 Form
N/A	A10. Address Type:
N/A	A16. Primary Provider (PCP) Name 2:
N/A	A17. Primary Provider (PCP) Phone 2:
N/A	A18. Primary Provider (PCP) Fax2:
E13. Where did patient reside at the time of	E13. Where did patient reside at the time of
hospitalization?	hospitalization?
☐ Private residence	☐ Private residence
☐ Rehabilitation facility	☐ Alcohol/Drug Abuse Treatment
☐ Group home/Retirement home	☐ Group home/Retirement home
☐ Assisted living/Residential care	☐ Homeless/Shelter
☐ Homeless/Shelter	☐ Hospitalized at birth
☐ Nursing home	☐ Jail/Prison
□ Unknown	☐ LTACH/Transitional Care (TCU)
☐ Other, specify:	☐ Mental Hospital
	☐ Nursing home
	☐ Rehabilitation facility
	☐ Hospice
	□ Unknown
	☐ Other, specify:
D1-4. Test 1-4:	D1-4. Test 1-4:
□ Rapid	□ Rapid
□ RT-PCR	☐ Molecular Assay
☐ Viral Culture	☐ Viral Culture
☐ Fluorescent Antibody	☐ Fluorescent Antibody
☐ Method Unknown/Note Only	☐ Method Unknown/Note Only
D1a-4a. Result:	D1a-4a. Result:
☐ Flu A (not subtyped)	☐ Flu A (no subtype)
☐ Flu B	☐ Flu B(no genotype)
□ Flu A & B	□ Flu A & B
☐ Flu A/B (Not Distinguished)	☐ Flu A/B (Not Distinguished)
□ 2009 H1N1	□ 2009 H1N1

☐ H1, Seasonal	☐ H1, Unspecified
☐ H1, Unspecified	☐ H3
☐ H3	☐ Flu A, Unsubtypable
☐ Flu A, Unsubtypable	☐ Flu B, Yamagata
☐ Negative	☐ Flu B, Victoria
☐ Unknown	□ Negative
	☐ Unknown Type
☐ Other, specify:	
E2 A	Other, specify:
E2. Acute conditions at admission (Check all that apply):	E2. Acute signs/symptoms at admission [within 2 weeks prior to positive flu test]:
☐ Acute respiratory illness	
☐ Asthma and/or COPD exacerbation	☐ Altered mental status/confusion
Fever	☐ Chest pain
☐ Pneumonia	☐ Congested/runny nose
☐ Other respiratory or cardiac conditions	☐ Conjunctivitis/pink eye
☐ Other, neither respiratory nor cardiac conditions	□ Cough
□ Unknown	□ Diarrhea
	☐ Fever/chills
	Headache
	☐ Myalgia/muscle aches
	☐ Nausea/vomiting
	Rash
	☐ Seizures
	☐ Shortness of breath/resp distress
	☐ Sore throat
	☐ Other, non-respiratory
E3. Date of onset of acute respiratory symptoms:	E3. Date of onset of acute respiratory symptoms [within 2
// □ Unknown	weeks prior to positive flu test]:
	// □ Unknown
E3a. If no respiratory symptoms, date of onset of acute	E4. Date of onset of acute condition resulting in current
illness resulting in hospitalization:	hospitalization:
miless resulting in mospitalizations	nospitalization.
/	/
	_
// Unknown	// □ Unknown
// □ Unknown E9i. Immunocompromised Condition □ Yes □	/ Unknown E10i. Immunocompromised Condition
/ ☐ Unknown E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months	Unknown E10i. Immunocompromised Condition ☐ Yes ☐ No/Unknown
/ □ Unknown E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200	Unknown E10i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200
/ ☐ Unknown E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months	/ □ Unknown E10i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer: current/in treatment or diagnosed in last 12 months
/ □ Unknown E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer diagnosis in last 12 months □ Complement deficiency □ HIV Infection	/ □ Unknown E10i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer: current/in treatment or diagnosed in last 12 months □ Complement deficiency □ HIV Infection
/ □ Unknown E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer diagnosis in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency	/ □ Unknown E10i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer: current/in treatment or diagnosed in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency
/ □ Unknown E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer diagnosis in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy	/ □ Unknown E10i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer: current/in treatment or diagnosed in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy
/ □ Unknown E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer diagnosis in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy □ Organ transplant	/ □ Unknown E10i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer: current/in treatment or diagnosed in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy □ Organ transplant
/ □ Unknown E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer diagnosis in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy □ Organ transplant □ Stem cell transplant (e.g., bone marrow transplant)	E10i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer: current/in treatment or diagnosed in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant)
/ □ Unknown E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer diagnosis in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy □ Organ transplant	E10i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer: current/in treatment or diagnosed in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy □ Organ transplant □ Stem cell transplant (e.g., bone marrow transplant) □ Steroid therapy (taken within 2 weeks of admission)
/ □ Unknown E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer diagnosis in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy □ Organ transplant □ Stem cell transplant (e.g., bone marrow transplant) □ Steroid therapy (taken within 2 weeks of admission)	E10i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer: current/in treatment or diagnosed in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant)
/ □ Unknown E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer diagnosis in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy □ Organ transplant □ Stem cell transplant (e.g., bone marrow transplant) □ Steroid therapy (taken within 2 weeks of admission) □ Other, specify	E10i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer: current/in treatment or diagnosed in last 12 months □ Complement deficiency □ HIV Infection □ Immunoglobulin deficiency □ Immunosuppressive therapy □ Organ transplant □ Stem cell transplant (e.g., bone marrow transplant) □ Steroid therapy (taken within 2 weeks of admission) □ Other, specify
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10k. Other □ Yes □ No/Unknown □ Lonknown
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify E9k. Other ☐ Yes ☐ No/Unknown ☐ Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C)	E10k. Other ☐ Yes ☐ No/Unknown ☐ Intravenous drug use ☐ Unknown ☐ Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer: current/in treatment or diagnosed in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Other, specify ☐ Intravenous drug use
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify ☐ E9k. Other ☐ Yes ☐ No/Unknown ☐ Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) ☐ Morbidly obese (ADULTS ONLY)	E10k. Other
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10k. Other
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify E9k. Other ☐ Yes ☐ No/Unknown ☐ Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) ☐ Morbidly obese (ADULTS ONLY) ☐ Obese ☐ Pregnant	E10k. Other
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify ☐ E9k. Other ☐ Yes ☐ No/Unknown ☐ Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) ☐ Morbidly obese (ADULTS ONLY) ☐ Obese ☐ Pregnant ☐ If pregnant, specify gestational age in weeks:	E10k. Other
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10k. Other
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10i. Immunocompromised Condition Yes No/Unknown AIDS or CD4 count < 200 Cancer: current/in treatment or diagnosed in last 12 months Complement deficiency HIV Infection Immunoglobulin deficiency Immunosuppressive therapy Organ transplant Stem cell transplant (e.g., bone marrow transplant) Steroid therapy (taken within 2 weeks of admission) Other, specify E10k. Other Yes No/Unknown Intravenous drug use Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) Systemic lupus erythematosus/SLE/Lupus Morbidly obese (ADULTS ONLY) Obese Pregnant If pregnant, specify gestational age in weeks:
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10k. Other
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10i. Immunocompromised Condition Yes No/Unknown AIDS or CD4 count < 200 Cancer: current/in treatment or diagnosed in last 12 months Complement deficiency HIV Infection Immunoglobulin deficiency Immunosuppressive therapy Organ transplant Stem cell transplant (e.g., bone marrow transplant) Steroid therapy (taken within 2 weeks of admission) Other, specify E10k. Other Yes No/Unknown Intravenous drug use Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) Systemic lupus erythematosus/SLE/Lupus Morbidly obese (ADULTS ONLY) Obese Pregnant If pregnant, specify gestational age in weeks: Unknown gestational age Post-partum (two weeks or less)
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10i. Immunocompromised Condition Yes No/Unknown AIDS or CD4 count < 200 Cancer: current/in treatment or diagnosed in last 12 months Complement deficiency HIV Infection Immunoglobulin deficiency Immunosuppressive therapy Organ transplant Stem cell transplant (e.g., bone marrow transplant) Steroid therapy (taken within 2 weeks of admission) Other, specify E10k. Other Yes No/Unknown Intravenous drug use Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) Systemic lupus erythematosus/SLE/Lupus Morbidly obese (ADULTS ONLY) Obese Pregnant If pregnant, specify gestational age in weeks: Unknown gestational age Post-partum (two weeks or less) Other, specify
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10i. Immunocompromised Condition Yes No/Unknown AIDS or CD4 count < 200 Cancer: current/in treatment or diagnosed in last 12 months Complement deficiency HIV Infection Immunoglobulin deficiency Immunosuppressive therapy Organ transplant Stem cell transplant (e.g., bone marrow transplant) Steroid therapy (taken within 2 weeks of admission) Other, specify E10k. Other Yes No/Unknown Intravenous drug use Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) Systemic lupus erythematosus/SLE/Lupus Morbidly obese (ADULTS ONLY) Obese Pregnant If pregnant, specify gestational age in weeks: Unknown gestational age Post-partum (two weeks or less) Other, specify H1f. Parainfluenza 4
E9i. Immunocompromised Condition □ Yes □ No/Unknown □ AIDS or CD4 count < 200 □ Cancer diagnosis in last 12 months □ Complement deficiency □ HIV Infection □ Immunoslobulin deficiency □ Immunosuppressive therapy □ Organ transplant □ Stem cell transplant (e.g., bone marrow transplant) □ Steroid therapy (taken within 2 weeks of admission) □ Other, specify □ E9k. Other □ Yes □ No/Unknown □ Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) □ Morbidly obese (ADULTS ONLY) □ Obese □ Pregnant □ If pregnant, specify gestational age in weeks: □ □ Unknown gestational age □ Post-partum (two weeks or less) □ Other, specify ■ H1f. Human metapneumovirus □ Yes, positive	E10i. Immunocompromised Condition Yes No/Unknown AIDS or CD4 count < 200 Cancer: current/in treatment or diagnosed in last 12 months Complement deficiency HIV Infection Immunoglobulin deficiency Immunosuppressive therapy Organ transplant Stem cell transplant (e.g., bone marrow transplant) Steroid therapy (taken within 2 weeks of admission) Other, specify E10k. Other Yes No/Unknown Intravenous drug use Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) Systemic lupus erythematosus/SLE/Lupus Morbidly obese (ADULTS ONLY) Obese Pregnant If pregnant, specify gestational age in weeks: Unknown gestational age Post-partum (two weeks or less) Other, specify H1f. Parainfluenza 4 Yes, positive
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10i. Immunocompromised Condition Yes No/Unknown AIDS or CD4 count < 200 Cancer: current/in treatment or diagnosed in last 12 months Complement deficiency HIV Infection Immunoglobulin deficiency Immunosuppressive therapy Organ transplant Stem cell transplant (e.g., bone marrow transplant) Steroid therapy (taken within 2 weeks of admission) Other, specify E10k. Other Yes No/Unknown Intravenous drug use Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) Systemic lupus erythematosus/SLE/Lupus Morbidly obese (ADULTS ONLY) Obese Pregnant If pregnant, specify gestational age in weeks: Unknown gestational age Post-partum (two weeks or less) Other, specify H1f. Parainfluenza 4 Yes, positive Yes, negative
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10i. Immunocompromised Condition Yes No/Unknown AIDS or CD4 count < 200 Cancer: current/in treatment or diagnosed in last 12 months Complement deficiency HIV Infection Immunoglobulin deficiency Immunosuppressive therapy Organ transplant Stem cell transplant (e.g., bone marrow transplant) Steroid therapy (taken within 2 weeks of admission) Other, specify E10k. Other Yes No/Unknown Intravenous drug use Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) Systemic lupus erythematosus/SLE/Lupus Morbidly obese (ADULTS ONLY) Obese Pregnant If pregnant, specify gestational age in weeks: Unknown gestational age Post-partum (two weeks or less) Other, specify H1f. Parainfluenza 4 Yes, positive Yes, negative Not tested/Unknown
E9i. Immunocompromised Condition ☐ Yes ☐ No/Unknown ☐ AIDS or CD4 count < 200 ☐ Cancer diagnosis in last 12 months ☐ Complement deficiency ☐ HIV Infection ☐ Immunoglobulin deficiency ☐ Immunosuppressive therapy ☐ Organ transplant ☐ Stem cell transplant (e.g., bone marrow transplant) ☐ Steroid therapy (taken within 2 weeks of admission) ☐ Other, specify	E10i. Immunocompromised Condition Yes No/Unknown AIDS or CD4 count < 200 Cancer: current/in treatment or diagnosed in last 12 months Complement deficiency HIV Infection Immunoglobulin deficiency Immunosuppressive therapy Organ transplant Stem cell transplant (e.g., bone marrow transplant) Steroid therapy (taken within 2 weeks of admission) Other, specify E10k. Other Yes No/Unknown Intravenous drug use Liver disease (e.g., cirrhosis, chronic hepatitis, hepatitis C) Systemic lupus erythematosus/SLE/Lupus Morbidly obese (ADULTS ONLY) Obese Pregnant If pregnant, specify gestational age in weeks: Unknown gestational age Post-partum (two weeks or less) Other, specify H1f. Parainfluenza 4 Yes, positive Yes, negative

☐ Yes, positive	☐ Yes, positive	
☐ Yes, negative	☐ Yes, negative	
☐ Not tested/Unknown	☐ Not tested/Unknown	
Date:/	Date:/	
H1h. Other, specify:	H1h. Rhinovirus/Enterovirus	
☐ Yes, positive	☐ Yes, positive	
☐ Yes, negative	☐ Yes, negative	
□ Not tested/Unknown	☐ Not tested/Unknown	
Date://	Date://	
N/A	H1i.Coronavirus (type):	
17/1	☐ Yes, positive	
	☐ Yes, negative	
	□ Not tested/Unknown	
TO DI COLO COLO COLO COLO COLO COLO COLO COL	Date://	
J2c. Please specify location for	Removed	
bronchopneumonia/pneumonia/consolidation/lobar		
infiltrate/air space density/opacity:		
☐ Single lobar		
☐ Multiple lobar (unilateral)		
☐ Multiple lobar (bilateral)		
□ Unknown		
K2a. If discharged alive, please indicate to where:	K2a. If discharged alive, please indicate to where:	
□ Home	☐ Private residence	
☐ Other hospital	☐ Alcohol/Drug Abuse Treatment	
☐ Hospice/Home hospice	☐ Assisted living/Residential Care	
☐ Homeless/Shelter	☐ Group home/Retirement home	
☐ Rehabilitation Facility	☐ Home with Services	
☐ Group home/Retirement home	☐ Homeless/Shelter	
☐ Assisted living/Residential Care	☐ Jail/Prison	
☐ Home with Services	☐ LTACH/Transitional Care (TCU)	
□ Nursing home	☐ Mental Hospital	
☐ Unknown	□ Nursing home	
☐ Other, specify:		
□ Other, specify:	Rehabilitation Facility	
	Hospice	
	Unknown	
	☐ Other, specify:	
M1. Did patient receive the influenza vaccine for the	Removed	
current influenza season?		
□ Yes		
□ No		
□ Unknown		
M2-M6. [vaccination history source]	M1-M4. [vaccination history source]	
□Yes	☐ Yes, full date known	
☐ Yes, specific date unknown	☐ Yes, specific date unknown	
□No	□No	
□ Unknown	□ Unknown	
□ Not Checked	□ Not Checked	
N/A	M1b-M4b. If patient < 9 yrs, specify vaccine type:	
	Injected Vaccine	
	Nasal Spray/FluMist	
	Combination of both	
	Unknown type	
	Olikilowii type	
	1	

B. 2014-2015 FluSurv-NET Influenza Surveillance Project_Vaccination History Telephone Survey

Question on 2013-14 Survey	Question on 2014-15 Survey
N/A	1b) What type of flu vaccine did [you / child's name] receive?
	□Injected Vaccine
	□Nasal Spray/FluMist

☐Combination of both
□Unknown type

C. 2014-2015 FluSurv-NET Influenza Surveillance Project_Consent Form

Question on 2013-14 Consent Form	Question on 2014-15 Consent Form
Hello. My name is from the[state]	Hello. My name is from the[state]
Department of Public Health. May I speak to	Department of Public Health. May I speak to
[patient's name /parent of [child's name]] . We are working	[patient's name /parent of [child's name]] . We are working
with the Centers for Disease Control and Prevention and other	with the Centers for Disease Control and Prevention and other
health departments to learn more about influenza disease or the	health departments to learn more about influenza disease or the
flu. To do this, we are talking to people who have been in the	flu. To do this, we are talking to people who have been in the
hospital with the flu. We want to look at things that may affect	hospital with the flu. We want to look at things that may affect
their illness and whether they were vaccinated against the flu.	their illness and whether they were vaccinated against the flu.
Because you/your child [or NAME if speaking with proxy] were in the hospital for the flu beginning on[day admitted], I would like to ask you a few questions about whether you/your child [or NAME if speaking with proxy] received the flu vaccine this season. This will take about five minutes. Your participation is voluntary and if you choose to refuse it will not affect any medical care or benefits you receive. All of your responses will be kept confidential as much as the law allows. You may refuse to answer any questions and may stop at any time. This information will help [State/Local Health Department] and CDC better describe influenza-associated hospitalizations. Additionally, this information may help us improve vaccination recommendations for flu and better protect the public's health. There is no other benefit to you for answering these questions. There is also no risk to you. If you have any questions about the study, you may call[state contact] at the Department of Public Health at XXX-XXX-XXXX. Do you have any questions before I begin? May I continue with this interview?	Because you/your child [or NAME if speaking with proxy] were in the hospital for the flu beginning on [day admitted], I would like to ask you a few questions about whether you/your child [or NAME if speaking with proxy] received the flu vaccine this season. This will take about five minutes. Your participation is voluntary and if you choose to refuse it will not affect any medical care or benefits you receive. All of your responses will be kept confidential as much as the law allows. You may refuse to answer any questions and may stop at any time. This information will help [State/Local Health Department] and CDC better describe influenza-associated hospitalizations. Additionally, this information may help us improve vaccination recommendations for flu and better protect the public's health. There is no other benefit to you for answering these questions. There is also no risk to you. If you have any questions about the study, you may call[state contact] at the Department of Public Health at XXX-XXX-XXXX. Do you have any questions before I begin? May I continue with this interview?
☐ Yes ☐ No	☐ Yes ☐ No
If YES, go to Appendix F.	If YES, go to Appendix 7.
If NO: Thank you for your time. Have a good day	If NO: Thank you for your time. Have a good day.